Alzheimer's disease trials.
1000 Alzheimer's disease trials, curated for APOE4 carriers — 532 of them recruiting. Each one translated into plain English, with our read on what it means for an APOE4 carrier.
- Non-carriers only, not for APOE4NCT00574132Bapineuzumab in Patients With Mild to Moderate Alzheimer's Disease (ApoE4 Non-Carrier)
This trial tested bapineuzumab, an infused antibody designed to bind and clear beta amyloid from the brain, against a placebo. It measured whether it helped…
- Drug trial for diagnosed APOE4 carriersNCT00575055Bapineuzumab in Patients With Mild to Moderate Alzheimer's Disease (ApoE4 Carrier)
This trial tested whether bapineuzumab, an antibody given by infusion that helps clear beta amyloid from the brain, could affect thinking and daily function in…
- Stratified by APOE4 genotype specificallyNCT01211782AC-1204 Long-term Efficacy Response Trial (ALERT Protocol)
This trial tests AC-1204, an oral ketogenic compound made from caprylic triglyceride, in people with mild to moderate Alzheimer's disease. The idea is that…
- Studies APOE4, but only in diagnosed patientsNCT01329536The Occurrence of the ApoE4 Allele in Agitated In-Patients With Late-Onset Alzheimer's Disease
This study looks at whether the APOE4 gene variant is more common in people with late-onset Alzheimer's who show agitation than in those who do not.…
- Carriers enrolled, but higher ARIA riskNCT01767311A Study to Evaluate Safety, Tolerability, and Efficacy of Lecanemab in Subjects With Early Alzheimer's Disease
This Phase 2 trial tested lecanemab, an anti-amyloid antibody given by infusion, in people with early Alzheimer's disease — either mild cognitive impairment or…
- APOE4 response explicitly analyzedNCT02292238Benfotiamine in Alzheimer's Disease: A Pilot Study
This trial is testing benfotiamine, a fat-soluble form of vitamin B1, in people with early memory problems or mild Alzheimer's. The idea is that boosting…
- Built exclusively for APOE 4/4 carriersNCT02565511A Study of CAD106 and CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease
This trial tested two investigational drugs, CAD106 (a vaccine-like immunotherapy targeting amyloid) and CNP520 (a small molecule targeting amyloid…
- Counseling study, not a treatment trialNCT02978729Telephone Versus Videoconference Communication for Remote Genetic Disclosure in the APOE4 Trial
This study compares two ways of delivering APOE genotype results and genetic counseling: by phone or by two-way video call. People aged 60-75 who are…
- Built specifically for APOE4 carriersNCT03131453A Study of CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease
This trial tested CNP520, a drug designed to reduce amyloid buildup in the brain, against a placebo in cognitively normal older adults at elevated risk for…
- Built exclusively for APOE4 homozygotesNCT03634007Gene Therapy for APOE4 Homozygote of Alzheimer's Disease
This Phase 1 trial is testing LX1001, a gene therapy delivered into the spinal fluid, in people who carry two copies of APOE4 and already have…
- Observational only, China-based populationNCT03653156China Cognition and Aging Study
This is a large observational study based in China, not a drug or treatment trial. Researchers are building a national database by following thousands of…
- Excludes APOE4 homozygotes (4/4 carriers)NCT03671889ExAblate Blood-Brain Barrier (BBB) Disruption for the Treatment of Alzheimer's Disease
This study tests whether a focused-ultrasound device, guided by MRI, can safely and temporarily open the blood-brain barrier in people with probable…
- Directly tests APOE4 carrier awarenessNCT03794141Genetic Information as a Life Style Change Motivator
This trial tests whether telling people they carry the APOE4 gene motivates them to make healthier lifestyle changes. Researchers also look at how learning…
- Imaging study, tied to one research centerNCT03816228Imaging of Brain Structural/Functional Connectivity and Amyloid and Tau Lesions in APOE4 Carriers.
This study uses brain scans to look at how brain connections, blood vessel health, and Alzheimer's-related proteins (amyloid and tau) relate to each other in…
- APOE4 genotype central to studyNCT03876314Physical Activity, Alzheimer's Disease and Cognition Relative to APOE Genotype
This trial is testing whether a structured physical activity program improves cognitive performance in middle-aged adults (40-65) who have a family history of…
- Open to carriers, but ARIA risk elevatedNCT03887455A Study to Confirm Safety and Efficacy of Lecanemab in Participants With Early Alzheimer's Disease
This Phase 3 trial tests lecanemab, an intravenous and subcutaneous antibody drug, against placebo in people with early Alzheimer's disease — either mild…
- Directly recruits APOE4 carriers onlyNCT03978052Prevention of Cognitive Decline in ApoE4 Carriers With Subjective Cognitive Decline After EGCG and a Multimodal Intervention
This trial is testing whether a green tea compound called EGCG, combined with a personalized lifestyle program covering diet, exercise, and cognitive training,…
- Directly recruits APOE4 carriersNCT04009629Dementia Risk and Dynamic Response to Exercise
This trial is testing how a single session of moderate aerobic exercise changes brain blood flow and blood biomarkers in older adults who carry the APOE4 gene.…
- Directly recruits APOE4 carriersNCT04430517Effects of Nicotinamide Riboside on Bioenergetics and Oxidative Stress in Mild Cognitive Impairment/Alzheimer's Dementia
This early-phase trial is testing nicotinamide riboside, a form of vitamin B3, in people who already have mild cognitive impairment or mild Alzheimer's…
- APOE4 carriers explicitly welcomedNCT04468659AHEAD 3-45 Study: A Study to Evaluate Efficacy and Safety of Treatment With Lecanemab in Participants With Preclinical Alzheimer's Disease and Elevated Amyloid and Also in Participants With Early Preclinical Alzheimer's Disease and Intermediate Amyloid
This Phase 3 trial is testing lecanemab, an anti-amyloid antibody drug, in people who are cognitively normal but have early amyloid buildup in their brains —…
- APOE4 carriers explicitly includedNCT04575337Study on Biomarkers for Early Diagnosis of Alzheimer's Disease
This is an observational study based in China that is tracking elderly people over five years to identify early biological markers of Alzheimer's disease.…
- Exclusively recruits APOE4 carriersNCT04693520Biomarker Effects of ALZ-801 in APOE4 Carriers With Early Alzheimer's Disease
This trial is testing ALZ-801, a daily oral pill, in people who already carry one or two copies of the APOE4 gene and have early Alzheimer's disease.…
- Built exclusively for APOE4/4 carriersNCT04770220An Efficacy and Safety Study of ALZ-801 in APOE4/4 Early AD Subjects
This Phase 3 trial is testing ALZ-801, an oral drug designed to reduce toxic amyloid clusters in the brain, against a placebo in people with early Alzheimer's…
- Directly recruits APOE4 carriersNCT05063851The Use of Memantine for Prevention of Alzheimer's Disease
This trial is testing whether memantine, an existing drug already used for moderate-to-severe Alzheimer's symptoms, can be given years before symptoms to help…
- Exclusively recruits APOE4 carriersNCT05161715Proof-of-concept, Open-label Study in Patients With Early Alzheimer's Disease
This trial is testing obicetrapib — a cholesterol-modifying drug — in people with early Alzheimer's disease. Researchers want to see how the drug moves through…
- Requires at least one APOE4 alleleNCT05245903Passive Sensor Identification of Digital Biomarkers to Assess Effects of Orally Administered Nicotinamide Riboside
This trial is testing whether a supplement called nicotinamide riboside (a form of vitamin B3) produces measurable changes in brain energy metabolism in people…
- Mentions APOE4, enrollment unconfirmed; MCI onlyNCT05321498Study to Assess the Efficacy of XPro1595 in Patients With Mild Cognitive Impairment With Biomarkers of Inflammation
This trial tests a drug called XPro1595 against a placebo in people with mild cognitive impairment (MCI) who show signs of brain inflammation. Researchers will…
- APOE4/4 specific, prior participants onlyNCT05400330Long-Term Follow-up of Gene Therapy for APOE4 Homozygote Alzheimer's Disease
This study follows people who already received LX1001, an experimental gene therapy that delivers a protective APOE2 gene into the brain. It mainly checks…
- Directly recruits APOE4 carriersNCT05599425Health Behavior Change in Midlife Adults at Risk for Alzheimer's Disease
This trial tests two versions of a healthy-living education program aimed at helping middle-aged adults make lasting lifestyle changes — better diet, more…
- Requires APOE4; for existing Alzheimer's dementiaNCT05809908Tricaprilin Phase 3 ALTER-AD (Alternative-Alzheimer Disease) Study
This trial tests tricaprilin, a drug taken by mouth twice a day, against a placebo. Researchers are measuring memory and thinking, daily function, and safety…
- Directly recruits APOE4 carriersNCT05880849Choline Effects - Pre-symptomatic AD
This Phase 1 trial is testing whether choline — a common dietary supplement — is safe and tolerable in people who carry the APOE4 gene and show no symptoms of…
- Actively recruits APOE4 carriersNCT05965414Safety and Pharmacokinetics of Single Ascending Doses and Multiple Ascending Doses of CS6253 in Healthy Volunteers
This trial is testing CS6253, an injected drug, in healthy volunteers to see if it is safe and how the body processes it. It is an Early Phase 1 trial, meaning…
- Drug trial — APOE4 carriers excludedNCT05986721Clinical Trial of AGB101 for Mild Cognitive Impairment
This trial tests AGB101, a once-daily pill (220 mg), against a placebo for 78 weeks in people with mild cognitive impairment likely due to Alzheimer's.…
- Explicitly welcomes APOE4 carriersNCT06043700A Community-Based Screening Program to Identify Participants at High Risk for Amyloid Pathology
This is a screening study, not a treatment trial. Researchers are using blood tests to find people who may have high levels of amyloid protein in the brain — a…
- Genetic study, APOE4 is the focusNCT06275243Polymorphism of ApoE in Alzheimer's Disease: Genetic Study in Castile and Leon (Spain)
This study is collecting cheek swabs from people in the Castile and Leon region of Spain to map how common the APOE4 gene variant is among people with and…
- APOE4/4 only, closed to new enrolleesNCT06304883Long-term Extension of Phase 3 Study of ALZ- 801 in APOE4/4 Early AD Subjects
This is a long-term extension of a Phase 3 trial testing ALZ-801, an oral drug designed to reduce toxic amyloid clumps in the brain. Researchers are tracking…
- Drug trial for symptomatic early Alzheimer'sNCT06335173A Study to Evaluate Efficacy and Safety of Intravenous Sabirnetug in Participants With Early Alzheimer's Disease (ALTITUDE-AD)
This trial tests sabirnetug, an antibody given by IV infusion every four weeks, against placebo. It looks at whether the drug slows decline in thinking and…
- APOE4 carriers central to studyNCT06335836The Effects of Social Isolation and Social Interaction on the Risk of Dementia Progression and Brain Function in SCD (Subjective Cognitive Decline, SCD)
This trial is studying how social isolation and social interaction affect the brain and the risk of progressing from subjective cognitive decline to more…
- APOE4 homozygotes explicitly excludedNCT06474013A Clinical Trial to Evaluate the Initial Safety and Efficacy of Repetitive BBB (Blood Brain Barrier) Disruption Using High Intensity Focused Ultrasound 'ExAblate 4000 Type 2.1' in Patients With Alzheimer's Disease
This trial is testing whether repeatedly opening the blood-brain barrier using a focused ultrasound device called ExAblate 4000 is safe and shows early signs…
- Not relevant to APOE4 carriersNCT06911944Amyloid Lowering for Alzheimer's in Down's With Donanemab Investigation
This trial is testing whether donanemab, an anti-amyloid antibody already approved for early Alzheimer's, can safely reduce amyloid buildup in the brains of…
- Actively recruits APOE4 carriersNCT07007208Biomarkers of the Locus Coeruleus Nucleus: Links With Early Tau Pathology, Cognition and Alzheimer's Disease Risk
This trial is studying a brain region called the locus coeruleus, which may show early signs of tau protein buildup before other areas affected in Alzheimer's.…
- Genotype-stratified, carriers likely eligibleNCT07027072Study to Evaluate the Efficacy and Safety of KDS2010 in Patients With Alzheimer's Disease With Mild Cognitive Impairment and Mild Dementia Due to Alzheimer's Disease
This trial is testing KDS2010, an experimental oral drug taken once daily, in people who have early Alzheimer's-related memory problems — either mild cognitive…
- Device study for diagnosed patients, not 4-specificNCT07049341Pilot Trial Evaluating Patient Experience With the MemorEM for Patients With Neurological Diseases
This pilot study asks people with neurological diseases, and their caregivers, how it feels to use the MemorEM, a head-worn device, over a long period. The…
- APOE4-aware design, not carrier-specificNCT07208344Intravenous Infusion of Umbilical Cord Blood as an Adjunctive Treatment for Alzheimer's Disease
This trial is testing whether infusing stem-like cells from donated umbilical cord blood — on top of a standard Alzheimer's drug — is safe and shows early…
- Carriers specifically sought, non-drug deviceNCT07222605Research Study for Patients With Neurological Diseases Which Evaluates the Patient Experience of the MemorEM Device
This pilot study tests a wearable head device called MemorEM in people with neurological diseases including Alzheimer's, Parkinson's, and frontotemporal…
- Directly recruits APOE4 carriers with MCINCT07392723ALA-enriched Nutrition for Prevention of Cognitive Decline in APOE4 Older Adults
This trial tests whether a daily dose of alpha-linolenic acid (ALA), a plant-based omega-3 found in flaxseed oil, affects memory and thinking, and the health…
- Exclusively enrolls APOE4 carriersNCT07399171Study to Evaluate the Effect of HT-4253 for the Prevention of Alzheimer's Disease in APOE4 Carriers
This Phase 2 trial is testing an experimental drug called HT-4253 in APOE4 carriers who already show early amyloid buildup in their blood but have no dementia…
- APOE4 4/4 carriers excludedNCT07456462Making Antibody Treatments More Effective in Early Alzheimer's Disease Using 3Tesla Magnetica Resonance
This study is testing whether advanced MRI scans and blood tests can predict how well lecanemab or donanemab are working in people with early Alzheimer's…
- Recruits APOE4/4 carriers, drug trialNCT07477431Levetiracetam for Persons at Risk for Alzheimer's Disease
This small pilot study tests whether very low doses of levetiracetam, an existing seizure drug, can calm overactive signaling in the brain's memory center.…
- Exclusively recruits APOE4 carriersNCT07516119Predicting Pre-dementia
This observational study is testing whether a multimodal prediction model — combining genetic risk scores, blood biomarkers, health record data, and wearable…
Copy a forum-ready post
Keep exploring
Educational, not medical advice. Trial decisions belong between you and your physician.